Twist Bioscience Corporation $TWST Stock Position Lifted by Bayforest Capital Ltd

Bayforest Capital Ltd lifted its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 33.3% in the 2nd quarter, HoldingsChannel reports. The firm owned 6,480 shares of the company’s stock after purchasing an additional 1,620 shares during the quarter. Bayforest Capital Ltd’s holdings in Twist Bioscience were worth $238,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. GAMMA Investing LLC boosted its stake in Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after buying an additional 303 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after purchasing an additional 302 shares during the period. Vanguard Personalized Indexing Management LLC lifted its stake in Twist Bioscience by 8.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company’s stock worth $222,000 after acquiring an additional 469 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in Twist Bioscience in the 1st quarter worth about $228,000. Finally, Xponance Inc. lifted its stake in Twist Bioscience by 22.0% in the 1st quarter. Xponance Inc. now owns 5,953 shares of the company’s stock worth $234,000 after acquiring an additional 1,072 shares in the last quarter.

Twist Bioscience Trading Down 4.0%

TWST stock opened at $30.75 on Friday. The company has a market cap of $1.86 billion, a P/E ratio of -21.21 and a beta of 2.38. Twist Bioscience Corporation has a twelve month low of $24.07 and a twelve month high of $55.33. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The business has a fifty day moving average of $27.93 and a 200-day moving average of $32.38.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. The company had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TWST shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, October 8th. Evercore ISI lowered their target price on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a report on Monday, August 4th. Finally, Barclays decreased their price objective on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, October 2nd. Nine analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average target price of $48.56.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 31,348 shares of the business’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $32.19, for a total value of $1,009,092.12. Following the completion of the transaction, the chief executive officer directly owned 601,212 shares of the company’s stock, valued at approximately $19,353,014.28. The trade was a 4.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Paula Green sold 9,724 shares of the business’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $313,015.56. Following the completion of the transaction, the senior vice president directly owned 114,678 shares of the company’s stock, valued at approximately $3,691,484.82. The trade was a 7.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,368 shares of company stock valued at $2,036,204 in the last ninety days. 3.01% of the stock is currently owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.